{"log_id": 8654348850777328475, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 5e-06, "average": 0.998446, "min": 0.992084}, "location": {"width": 745, "top": 254, "height": 37, "left": 267}, "words": "尚未进行关于对驾驶和机械操作的影响研究。目前还没有数据表明,托珠单抗治疗会"}, {"probability": {"variance": 0, "average": 0.99927, "min": 0.997566}, "location": {"width": 244, "top": 302, "height": 27, "left": 226}, "words": "影响驾驶和机械操作的能力"}, {"probability": {"variance": 4e-06, "average": 0.998527, "min": 0.994405}, "location": {"width": 103, "top": 343, "height": 24, "left": 267}, "words": "实验室检查"}, {"probability": {"variance": 0, "average": 0.989834, "min": 0.989834}, "location": {"width": 21, "top": 340, "height": 23, "left": 1148}, "words": "司"}, {"probability": {"variance": 8e-06, "average": 0.997594, "min": 0.990737}, "location": {"width": 161, "top": 381, "height": 24, "left": 271}, "words": "中性粒细胞减少症"}, {"probability": {"variance": 9e-06, "average": 0.998243, "min": 0.987068}, "location": {"width": 744, "top": 412, "height": 34, "left": 268}, "words": "托珠单抗治疗可伴有中性粒细胞减少症发生率的升高。在临床试验中,治疗相关性中"}, {"probability": {"variance": 2.6e-05, "average": 0.997601, "min": 0.971057}, "location": {"width": 648, "top": 453, "height": 33, "left": 227}, "words": "性粒细胞减少症通常并不伴有严重感染(见【不良反应】实验室异常部分)"}, {"probability": {"variance": 0.004354, "average": 0.984422, "min": 0.576292}, "location": {"width": 744, "top": 490, "height": 34, "left": 270}, "words": "中性粒细胞计数减少(即ANC<2×10%)的患者需慎用托珠单抗治疗。中性粒细胞绝"}, {"probability": {"variance": 0.016895, "average": 0.957944, "min": 0.426596}, "location": {"width": 472, "top": 533, "height": 30, "left": 229}, "words": "对计数低于0.5x10L的患者不推荐使用托珠单抗治疗"}, {"probability": {"variance": 0.003718, "average": 0.988694, "min": 0.622946}, "location": {"width": 739, "top": 567, "height": 37, "left": 277}, "words": "RA患者应在治疗开始后4至8周监测中性粒细胞,此后根据临床操作规范进行监测"}, {"probability": {"variance": 8.3e-05, "average": 0.995805, "min": 0.95418}, "location": {"width": 476, "top": 611, "height": 33, "left": 229}, "words": "根据ANC结果推荐的剂量调整,见【用法用量】部分"}, {"probability": {"variance": 6.6e-05, "average": 0.995437, "min": 0.977353}, "location": {"width": 117, "top": 655, "height": 25, "left": 275}, "words": "血小板减少症"}, {"probability": {"variance": 2.4e-05, "average": 0.998632, "min": 0.969163}, "location": {"width": 744, "top": 686, "height": 34, "left": 273}, "words": "托珠单抗治疗可伴有血小板计数的减少。在临床试验中,治疗相关性血小板减少通常"}, {"probability": {"variance": 2.8e-05, "average": 0.997542, "min": 0.975304}, "location": {"width": 488, "top": 729, "height": 30, "left": 234}, "words": "不伴随严重出血事件(见【不良反应】实验室异常部分)"}, {"probability": {"variance": 0.019198, "average": 0.948626, "min": 0.441414}, "location": {"width": 744, "top": 763, "height": 37, "left": 273}, "words": "血小板计数低于100×10%l的患者需慎用托珠单抗治疗,血小板计数<50×103l的"}, {"probability": {"variance": 4e-06, "average": 0.997389, "min": 0.99382}, "location": {"width": 262, "top": 807, "height": 33, "left": 232}, "words": "患者不推荐使用托珠单抗治疗"}, {"probability": {"variance": 3e-06, "average": 0.998787, "min": 0.99336}, "location": {"width": 743, "top": 842, "height": 35, "left": 277}, "words": "RA患者应在治疗开始后4至8周监测血小板,此后根据临床操作规范进行监测。根"}, {"probability": {"variance": 9e-06, "average": 0.997819, "min": 0.988215}, "location": {"width": 464, "top": 885, "height": 33, "left": 233}, "words": "据血小板计数推荐的剂量调整,见【用法用量】部分"}, {"probability": {"variance": 1.5e-05, "average": 0.996507, "min": 0.987426}, "location": {"width": 184, "top": 929, "height": 25, "left": 277}, "words": "肝脏氨基转移酶升高"}, {"probability": {"variance": 0.000158, "average": 0.99624, "min": 0.92403}, "location": {"width": 726, "top": 960, "height": 34, "left": 276}, "words": "在临床试验中,接受托珠单抗治疗的患者中可出现肝脏氨基转移酶轻度和中度升高"}, {"probability": {"variance": 0.000107, "average": 0.99601, "min": 0.935681}, "location": {"width": 793, "top": 999, "height": 35, "left": 235}, "words": "但未进展至肝功能损伤(见【不良反应】实验室异常部分)。当潜在肝毒性药物(如MTX)"}, {"probability": {"variance": 0.004342, "average": 0.983908, "min": 0.689306}, "location": {"width": 410, "top": 1044, "height": 28, "left": 248}, "words": "与托珠单抗联合用药时,该事件发生的几率增加"}, {"probability": {"variance": 0.002817, "average": 0.988282, "min": 0.668325}, "location": {"width": 727, "top": 1078, "height": 36, "left": 279}, "words": "在ALT或AST升高超过1.5倍正常上限的患者中开始使用托珠单抗时应特别谨慎"}, {"probability": {"variance": 2.3e-05, "average": 0.997574, "min": 0.973647}, "location": {"width": 613, "top": 1119, "height": 35, "left": 239}, "words": "对于ALT或AST升高超过5倍正常上限的患者,不推荐使用托珠单抗"}, {"probability": {"variance": 8e-06, "average": 0.997978, "min": 0.988494}, "location": {"width": 740, "top": 1156, "height": 36, "left": 284}, "words": "RA患者应在治疗开始后4至8周监测ALT和AST,此后根据临床操作规范进行监测"}, {"probability": {"variance": 4.4e-05, "average": 0.996041, "min": 0.976237}, "location": {"width": 483, "top": 1198, "height": 34, "left": 239}, "words": "根据氨基转移酶推荐的剂量调整,见【用法用量】部分"}, {"probability": {"variance": 2e-06, "average": 0.99906, "min": 0.996764}, "location": {"width": 85, "top": 1243, "height": 25, "left": 284}, "words": "血脂参数"}, {"probability": {"variance": 5.7e-05, "average": 0.99692, "min": 0.96347}, "location": {"width": 745, "top": 1273, "height": 37, "left": 282}, "words": "在研究中已发现血脂参数(如总胆固醇、甘油三酯和或低密度脂蛋白胆固醇)有所升"}, {"probability": {"variance": 0.000151, "average": 0.993849, "min": 0.947997}, "location": {"width": 337, "top": 1318, "height": 31, "left": 241}, "words": "高(见【不良反应】实验室异常部分)"}, {"probability": {"variance": 0.005435, "average": 0.985291, "min": 0.544765}, "location": {"width": 737, "top": 1352, "height": 35, "left": 291}, "words": "RA患者应在治疗开始后4至8周对血脂参数进行评估。依照当地高脂血症治疗的临"}, {"probability": {"variance": 3e-06, "average": 0.998722, "min": 0.993495}, "location": {"width": 264, "top": 1397, "height": 30, "left": 243}, "words": "床指导原则,对患者进行管理"}, {"probability": {"variance": 1e-06, "average": 0.998611, "min": 0.996414}, "location": {"width": 102, "top": 1439, "height": 25, "left": 289}, "words": "心血管风险"}, {"probability": {"variance": 0.080323, "average": 0.781394, "min": 0.381013}, "location": {"width": 96, "top": 1437, "height": 44, "left": 1010}, "words": "股份"}, {"probability": {"variance": 0.000726, "average": 0.990093, "min": 0.882111}, "location": {"width": 709, "top": 1470, "height": 38, "left": 291}, "words": "RA患者心血管疾病风险增加,风险因素(例如高血压,高脂血症)应作为"}, {"probability": {"variance": 1e-05, "average": 0.997674, "min": 0.989366}, "location": {"width": 202, "top": 1517, "height": 28, "left": 246}, "words": "护理的一部分进行管理"}, {"probability": {"variance": 1.3e-05, "average": 0.997861, "min": 0.987572}, "location": {"width": 233, "top": 1554, "height": 30, "left": 251}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0, "average": 0.918419, "min": 0.918419}, "location": {"width": 70, "top": 1505, "height": 73, "left": 1015}, "words": "★"}], "language": 3}